Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status.
Click 'More' for important dataset description and footnotes

Dataset and data visualization details:
These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected.
Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type.
** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group.
Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis.
Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

本数据集收录了美国疾病控制与预防中心（CDC）COVID-19疫情追踪网站上的疫苗接种状态下的COVID-19病例和死亡率的统计数据。数据更新于2022年10月21日，并于11月18日存档，最终修订于2023年2月22日。这些数据反映了截至2022年9月24日，样本采集日期为阳性的病例，以及截至2022年9月3日，样本采集日期为阳性的死亡病例。

疫苗接种状态：完成美国食品药品监督管理局（FDA）授权或批准的COVID-19疫苗初级系列接种的人员，若在完成初级系列后≥14天内，呼吸样本中检测到SARS-CoV-2 RNA或抗原，则被视为已接种疫苗。未接种疫苗的人员，若呼吸样本中检测到SARS-CoV-2 RNA或抗原，且未证实已接种COVID-19疫苗，则被视为未接种疫苗。部分接种疫苗的人员，若已接种至少一剂FDA授权的疫苗，但未在采集检测到SARS-CoV-2 RNA或抗原的样本前≥14天完成初级系列接种，则被排除在外。

额外或加强剂：完成初级系列接种并接种额外或加强剂的人员，若在接种任何COVID-19疫苗的额外或加强剂后≥14天，呼吸样本中检测到SARS-CoV-2 RNA或抗原，则被视为已接种额外或加强剂。对于18岁及以上的人群，数据从2021年9月24日开始的该周开始绘制，这是美国疾病控制与预防中心（CDC）首次建议65岁及以上成年人以及某些人群、高风险职业和机构环境中的成人接种COVID-19加强剂。对于12-17岁的人群，数据从2021年12月26日开始的该周开始绘制，这是首次建议16-17岁青少年接种加强剂的两周后。对于5-11岁的人群，数据从2022年6月5日开始的该周开始绘制，这是首次建议5-11岁儿童接种加强剂的两周后。对于50岁及以上的人群，第二剂加强剂的数据从2022年3月29日开始的该周开始绘制，这是建议第二剂加强剂的时间。垂直线表示美国COVID-19疫苗接种政策发生变化的日期（详细信息见上文）。报告数据基于初级系列疫苗类型，而非额外或加强剂疫苗类型。加强剂疫苗类型可能与初级系列疫苗类型不同。

**由于病例和关联死亡病例的免疫状态数据不可用，无法区分免疫抑制人群中的额外剂和加强剂。这是一个相关考虑因素，因为疫苗在这组人群中的有效性可能较低。

死亡病例：COVID-19相关死亡发生在有COVID-19诊断记录的人身上，并且死亡；卫生部门工作人员通过生命记录、公共卫生调查或其他数据来源进行审查，以做出死亡判定。根据患者进行COVID-19检测的时间报告COVID-19死亡率的疫苗接种状态，而不是患者死亡的时间。死亡通常发生在COVID-19诊断后的30天内。

参与地区：目前，这些31个卫生部门，它们定期将病例监测与免疫信息系统数据链接，包括在病例发生率估计中：阿拉巴马州、亚利桑那州、阿肯色州、加利福尼亚州、科罗拉多州、康涅狄格州、哥伦比亚特区、佛罗里达州、乔治亚州、爱达荷州、印第安纳州、堪萨斯州、肯塔基州、路易斯安那州、马萨诸塞州、密歇根州、明尼苏达州、内布拉斯加州、新泽西州、新墨西哥州、纽约州、纽约市（纽约）、北卡罗来纳州、费城（宾夕法尼亚州）、罗德岛州、南达科他州、田纳西州、德克萨斯州、犹他州、华盛顿州和西弗吉尼亚州；30个地区还报告了接种疫苗和未接种疫苗人群的死亡。这些地区代表着美国总人口的72%以及所有十个卫生与公众服务地区。病例数据